مباشر

BioPharma DiveBayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline Thermo FisherThermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider - PharmiWeb.com BioPharma DiveNovo hikes guidance on Wegovy pill’s fast sales start Endpoints NewsMadrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts Endpoints NewsFormer Orbital scientists launch new mRNA therapy startup FierceBiotechBioCryst scraps eye candidate to focus on rare diseases Clinical OMICsNext Generation CRISPR Gene Editing Could Help Target Cancer Cells Endpoints NewsAvalo scores Phase 2 success in comeback bid, raises $375M BioPharma DiveAvalo shares spike on skin drug data; BioNTech to cut staff Promega BlogA Historic Milestone for PROTAC Research: What Vepdegestrant’s FDA Decision Means for Drug Discovery Clinical OMICsMatthew Rabinowitz: Engineering a New Era of Diagnosis Endpoints NewsGSK goes to China for $1B siRNA deal in Arrowhead's obesity lane

Promega Blog ٦ مايو ٢٠٢٦

A Historic Milestone for PROTAC Research: What Vepdegestrant’s FDA Decision Means for Drug Discovery

Vepdegestrant, the first approved PROTAC therapeutic for ESR1-mutated ER+/HER2– advanced breast cancer, received FDA approval on May 1, 2026. It marks a signifi...

Vepdegestrant, the first approved PROTAC therapeutic for ESR1-mutated ER+/HER2– advanced breast cancer, received FDA approval on May 1, 2026. It marks a significant advancement in targeted protein degraders, demonstrating a new drug development approach focused on protein degradation rather than inhibition, with broader implications for future therapies in challenging cancer types. The post A Historic Milestone for PROTAC Research: What Vepdegestrant’s FDA Decision Means for Drug Discovery appeared first on Promega Connections .